Literature DB >> 24629499

Underutilization of local salvage therapy after radiation therapy for prostate cancer.

Henry Tran1, Jaime Kwok1, Tom Pickles2, Scott Tyldesley2, Peter C Black3.   

Abstract

OBJECTIVE: To evaluate the rates at which patients are offered and receive local salvage therapy (LST) after failure of primary radiotherapy for localized prostate cancer, as it is the only potentially curative treatment for localized recurrence but appears to be underutilized when compared with androgen-deprivation therapy (ADT) or observation.
MATERIALS AND METHODS: Patients with localized prostate cancer who received primary radiotherapy with curative intent between 1999 and 2000 were identified in the British Columbia Tumour Registry. Exclusion criteria included patient age >72 years, prostate-specific antigen>40 ng/ml, and clinical stage T4 at diagnosis. Data on clinicopathologic features, primary therapy, prostate-specific antigen kinetics, and salvage therapy were collected retrospectively. Radiation failure was defined as biochemical recurrence according to the Phoenix criteria or by initiation of salvage therapy.
RESULTS: Of 1,782 patients treated in the study period, 1,067 met inclusion criteria. Of these, 257 failed radiation therapy. Radiation therapy failure was managed with observation (>12 mo) in 126 patients and ADT in 119. Of the observed patients, 66 subsequently received ADT. Five patients (1.8%) received LST (3 radical prostatectomy and 2 brachytherapy).
CONCLUSIONS: Only 2% of patients relapsing after radiation therapy for localized prostate cancer received LST. Although the benefits of LST are unproven, these findings reveal a possible underutilization of LST and indicate a need for enhanced collaboration between specialties to optimize care of this challenging cohort.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Cryotherapy; Prostatic neoplasms; Radiotherapy; Salvage brachytherapy; Salvage radical prostatectomy; Salvage therapy

Mesh:

Substances:

Year:  2014        PMID: 24629499     DOI: 10.1016/j.urolonc.2013.12.014

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  28 in total

1.  Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526).

Authors:  Randall J Brenneman; Edward Soffen; Hiram A Gay; Peter F Orio; John P Christodouleas; John C Baumann; Brian C Baumann
Journal:  Transl Androl Urol       Date:  2019-07

2.  Salvage prostate brachytherapy after definitive external radiation: tried and now tested.

Authors:  Young Kwok; Mannat Narang; Jason K Molitoris
Journal:  Transl Androl Urol       Date:  2019-07

Review 3.  High-dose-rate brachytherapy as salvage modality for locally recurrent prostate cancer after definitive radiotherapy : A systematic review.

Authors:  Georgios Chatzikonstantinou; Nikolaos Zamboglou; Claus Rödel; Eleni Zoga; Iosif Strouthos; Saeed Ahmed Butt; Nikolaos Tselis
Journal:  Strahlenther Onkol       Date:  2017-06-16       Impact factor: 3.621

4.  A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).

Authors:  Juanita M Crook; Peixin Zhang; Thomas M Pisansky; Edouard J Trabulsi; Mahul B Amin; William Bice; Gerard Morton; Nadeem Pervez; Eric Vigneault; Charles Catton; Jeff Michalski; Mack Roach; David Beyer; Ashesh Jani; Eric Horwitz; Viroon Donavanik; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-10-09       Impact factor: 7.038

Review 5.  Salvage Therapy Options for Local Prostate Cancer Recurrence After Primary Radiotherapy: a Literature Review.

Authors:  Nicole M Golbari; Aaron E Katz
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

6.  Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).

Authors:  Juanita Crook; Joseph P Rodgers; Thomas M Pisansky; Edouard J Trabulsi; Mahul B Amin; William Bice; Gerard Morton; Albert D Murtha; Eric Vigneault; Joelle Helou; Jeff M Michalski; Mack Roach; David Beyer; Ashesh B Jani; Eric M Horwitz; Adam Raben; Stephanie Pugh; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-11-03       Impact factor: 7.038

7.  Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy.

Authors:  Patrick A Kenney; Cayce B Nawaf; Mahmoud Mustafa; Sijin Wen; Matthew F Wszolek; Curtis A Pettaway; John F Ward; John W Davis; Louis L Pisters
Journal:  Can J Urol       Date:  2016-06       Impact factor: 1.344

8.  Health service underutilization and its associated factors for chronic diseases patients in poverty-stricken areas in China: a multilevel analysis.

Authors:  Haiyan Hu; Weiyan Jian; Hongqiao Fu; Hao Zhang; Jay Pan; Winnie Yip
Journal:  BMC Health Serv Res       Date:  2021-07-18       Impact factor: 2.655

9.  Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer.

Authors:  Khurram M Siddiqui; Michele Billia; Andrew Williams; Ali Alzahrani; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2015 Sep-Oct       Impact factor: 1.862

10.  Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes.

Authors:  Brecht Devos; Walid Al Hajj Obeid; Colin Andrianne; Romain Diamand; Alexandre Peltier; Wouter Everaerts; Hein Van Poppel; Roland Van Velthoven; Steven Joniau
Journal:  World J Urol       Date:  2019-01-21       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.